1. Home
  2. GLMD vs REVB Comparison

GLMD vs REVB Comparison

Compare GLMD & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galmed Pharmaceuticals Ltd.

GLMD

Galmed Pharmaceuticals Ltd.

HOLD

Current Price

$0.57

Market Cap

4.4M

Sector

Health Care

ML Signal

HOLD

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$1.07

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLMD
REVB
Founded
2000
2020
Country
Israel
United States
Employees
N/A
9
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4M
4.2M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
GLMD
REVB
Price
$0.57
$1.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.5M
72.5K
Earning Date
05-21-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$0.47
52 Week High
$2.34
$3.34

Technical Indicators

Market Signals
Indicator
GLMD
REVB
Relative Strength Index (RSI) 42.73 40.87
Support Level $0.50 $1.03
Resistance Level $0.69 $1.20
Average True Range (ATR) 0.04 0.07
MACD -0.01 -0.01
Stochastic Oscillator 16.78 35.78

Price Performance

Historical Comparison
GLMD
REVB

About GLMD Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

Share on Social Networks: